New Compounds For Tailored Therapy Against MLL-rearranged Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$326,401.00
Summary
Some of the worst leukaemia survival rates are found in children and adults whose leukaemias display abnormalities of the MLL gene and alternative therapies are therefore urgently required for these patients. The aim of this project is to develop new compounds that specifically inhibit this abnormal gene and in turn inhibit the growth of these cells in the patient. In this way we hope to provide new and more effective therapies for patients affected with this aggressive type of leukaemia.
Chronic myeloid leukaemia was almost always fatal before the development of imatinib a decade ago, the first tyrosine kinase inhibitor (TKI) developed to treat a human cancer. There are now more potent TKIs that are effective in cases of resistance to imatinib. The challenge now is to optimise the achievement of remissions using these drugs and convert CML into a curable condition. This will be the focus of my NHMRC Practitioner Fellowship over the next 5 years.
The Role Survivin And XIAP (X-linked Inhibitor Of Apoptosis Protein) As Biomarkers And Therapeutic Targets In Paediatric Acute Myeloid Leukaemia.
Funder
National Health and Medical Research Council
Funding Amount
$294,218.00
Summary
I am a Paediatric Haematologist/Oncologist focussing on new treatments for childhood acute myeloid leukaemia. This study is examining the effects of conventional and novel therapies on two proteins that prevent cell death in acute myeloid leukaemia. The study will also develop clinical trials of new drugs targeting these proteins.
Using Mouse Models To Identify Better Therapies For Acute Leukemia And Myelodysplasia
Funder
National Health and Medical Research Council
Summary
Despite great advances in the understanding of the genes that cause cancers of the blood, cure rates for patients with acute leukemia, or a more indolent form called myelodyspslaia, has not improved significantly over the last 20 years, with the majority of patients dying from resistant or recurrent disease within 5 years. Our research will use mouse models of acute leukemia and myelodysplasia to identify the critical genetic pathways that drive these diseases and to design and test new therapie ....Despite great advances in the understanding of the genes that cause cancers of the blood, cure rates for patients with acute leukemia, or a more indolent form called myelodyspslaia, has not improved significantly over the last 20 years, with the majority of patients dying from resistant or recurrent disease within 5 years. Our research will use mouse models of acute leukemia and myelodysplasia to identify the critical genetic pathways that drive these diseases and to design and test new therapies that can be taken into clinical trials.Read moreRead less